Brain cannabinoid systems as targets for the therapy of neurological disorders

Neurobiology of Disease

Volumn 5, Issue 6, 1998, Pages 534-551

  Consroe, Paul ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cannabinoid receptor; Cannabinoids; Cannabis; Marijuana; Neurological disorders

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; NABILONE; RIMONABANT; UNCLASSIFIED DRUG;

AMNESIA; ARTICLE; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DEMENTIA; DYSTONIA; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; SEIZURE; SPASTICITY; SPINAL CORD INJURY; VOMITING;

EID: 0032451280     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1998.0220     Document Type: Article

References (159)

1. Abel E. L. Marijuana: The First Twelve Thousand Years. 1980;Plenum Press, New York.
2. Mechoulam R. The pharmacohistory ofCannabis sativa. Cannabinoids as Therapeutic Agents. 1986;CRC Press, Boca Raton. p. 1-19.
3. Gaoni Y., Mechoulam R. Isolation, structure elucidation and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
4. Pertwee R. G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:1987;189-261.
5. Herkenham M. Localization of cannabinoid receptors in brain and periphery. Pertwee R. G. Cannabinoid Receptors. 1995;145-166 Academic Press, London.
6. Howlett A. C., Bidaut-Russell M., Devane W. A., Melvin L. S., Johnson M. R., Herkenham M. The cannabinoid receptor: Biochemical, anatomical and behavioral characterization. Trends Neurosci. 13:1990;420-423.
7. Martin B. R., Welch S. P., Abood M. Progress toward understanding the cannabinoid receptor and its second messenger systems. Adv. Pharmacol. 25:1994;341-397.
8. Pertwee R. G. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors: An overview. Pertwee R. G. Cannabinoid Receptors. 1995;1-34 Academic Press, London.
9. Howlett A. C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
10. Childers S. R., Deadwyler S. A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 52:1996;819-827.
11. 12. Pharmacol. Ther. 74:1997;129-180.
12. Matsuda L. A., Bonner T. I. Molecular biology of the cannabinoid receptor. Pertwee R. G. Cannabinoid Receptors. 1995;117-143 Academic Press, London.
13. Abood M. E., Martin B. R. Molecular neurobiology of the cannabinoid receptor. Int. Rev. Neurobiol. 39:1996;197-221.
14. Burstein S. H., Young J. K., Wright G. E. Relationships between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents. Biochem. Pharmacol. 50:1995;1735-1742.
15. Mechoulam R., Shabat S. B., Hanus L., Fride E., Bayewitch M., Vogel Z. Endogenous cannabinoid ligands. Adv. Exp. Med. Biol. 402:1996;95-101.
16. Di Marzo V., De Petrocellis L. The endogenous cannabinoid signaling system: Chemistry, biochemistry and physiology. Internet J. Sci. Biol. Chem. 1997.
17. Glass M., Brotchie J. M., Maneuf Y. P. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur. J. Neurosci. 9:1997;199-203.
18. Consroe P., Snider S. R. Therapeutic potential of cannabinoids in neurological disorders. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;21-49 CRC Press, Boca Raton.
19. Consroe P., Sandyk R. Potential role of cannabinoids for therapy of neurological disorders. Bartke A., Murphy L. Marijuana/Cannabinoids: Neurobiology and Neurophysiology. 1992;459-524 CRC Press, Boca Raton.
20. Devane W. A., Dysarz F. A., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
21. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
22. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
23. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
24. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
25. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
26. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
27. Mailleux P., Vanderhaeghen J. J. Distribution of neuronal cannabinoid receptor in the adult brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
28. Glass M., Dragunow M., Faull R. L. M. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 77:1997;299-318.
29. Felder C. C., Nielsen A., Briley E. M., Palkovits M., Priller J., Axelrod J., Nguyen D. N., Richardson J. M., Riggin R. M., Koppel G. A., Paul S. M., Becker G. W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
30. Milligan G., Bond R. A., Lee M. Inverse agonism: Pharmacological curiosity or potential therapeutic strategy. Trends Pharmacol. Sci. 16:1995;10-13.
31. Mechoulam R., Devane W. A., Glaser R. Cannabinoid geometry and biological activity. Bartke A., Murphy L. Marijuana/Cannabinoids: Neurobiology and Neurophysiology. 1992;1-33 CRC Press, Boca Raton.
32. Thomas B. F., Gilliam A. F., Burch D. F., Roche M. J., Seltzman H. H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther. 285:1998;285-292.
33. 9. Life Sci. 63:1998;PL1-PL6.
34. 935. J. Neurosci. 16:1996;8057-8066.
35. 9. Eur. J. Pharmacol. 323:1997;3-4.
36. Reggio P. H., Bramblett R. D., Yuknavich H., Selzman H. H., Fleming D. N., Fernando S. R., Stevenson L. A., Pertwee R. G. The design, synthesis and testing of desoxy-CBD: Further evidence for a region of steric interference at the cannabinoid receptor. Life Sci. 56:1995;2025-2032.
37. Shen M., Piser T. M., Seybold V. S., Thayer S. A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334.
38. 1. Br. J. Pharmacol. 118:1996;2199-2205.
39. Pertwee R. G., Griffin G., Fernando S., Li X., Hill A., Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56:1995;1949-1955.
40. Hosohata K., Quock R. M., Hoshata Y., Burkey T. H., Makriyannis A., Consroe P., Rooeske W. R., Yamamura H. I. AM630 is a competitive cannabinoid antagonist in the guinea pig brain. Life Sci. 61:1997;PL115-PL118.
41. 1. Life Sci. 62:1998;PL109-PL113.
42. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
43. Mackie K., Devane W. A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
44. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
45. 9. J. Pharmacol. Exp. Ther. 272:1995;699-707.
46. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.-C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
47. 12. Mol. Pharmacol. 48:1995;443-450.
48. 1. Br. J. Pharmacol. Proc. Suppl. 116:1995;46p.
49. 1. Br. J. Pharmacol. 118:1996;2053-2058.
50. 9. J. Pharmacol. Exp. Ther. 277:1996;586-594.
51. McGregor I. S., Dastur F. N., McLellan R. A., Brown R. E. Cannabinoid modulation of rat pup ultrasonic vocalizations. Eur. J. Pharmacol. 313:1996;43-49.
52. 1. Psychopharmacology. 126:1996;165-172.
53. 1. Life Sci. 58:1996;PL103-PL110.
54. Gifford A. N., Ashby C. R. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR141716A. J. Pharmacol. Exp. Ther. 277:1996;1431-1436.
55. Richardson J. D., Aanonsen L., Hargreaves K. M. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
56. 1. Psychopharmacology. 132:1997;104-106.
57. 1. NeuroReport. 8:1997;491-496.
58. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.-P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J. Biol. Chem. 272:1997;22330-22339.
59. 1. Eur. J. Pharmacol. 334:1997;R1-R2.
60. Ehlert F. J. The relationship between muscarinic receptor occupany and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 28:1985;410-421.
61. Burkey T. H., Quock R. M., Consroe P., Ehlert F. J., Hosohata Y., Roeske W. R., Yamamura H. I. Relative efficacies of cannabinoid receptor agonists in the mouse brain. Eur. J. Pharmacol. 336:1997;295-298.
62. Noth J. Trends in the pathophysiology and pharmacotherapy of spasticity. J. Neurol. 238:1991;131-139.
63. Adams R. D., Victor M., Ropper A. H. Principles of Neurology. 1997;McGraw-Hill, New York.
64. Petro D. J. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics. 21:1980;81-85.
65. Randall R. C. Muscle Spasm, Pain & Marijuana Therapy. 1991;Galen Press, Washington.
66. Grinspoon L., Bakalar J. B. Marihuana: The Forbidden Medicine. 1993;Yale Univ. Press, New Haven.
67. Dunn M., Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia. 12:1974;175.
68. Malec J., Harvey R. F., Cayner J. J. Cannabis effect on spasticity in spinal cord injury. Arch. Phys. Med. Rehab. 63:1982;116-118.
69. Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38:1997;44-48.
70. Meinck H. M., Schonle P. W., Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J. Neurol. 236:1989;120-122.
71. Greenberg H. S., Werness S. A. S., Pugh J. E., Andrus R. O., Anderson D. J., Domino E. F. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin. Pharmacol. Ther. 55:1994;324-328.
72. 9. J. Clin. Pharmacol. 21:1981;413s-416s.
73. Clifford D. B. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. 13:1983;669-671.
74. Ungerleider J. T., Andyrsiak T., Fairbanks L., Ellison G. W., Myers L. W. Δ-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv. Alcohol Substance Abuse. 7:1987;39-50.
75. 9. Clin. Pharmacol. Ther. 39:1986;198.
76. Maurer M., Henn V., Dittrich A., Hofmann A. Δ-9-Tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. Psychiatr. Clin. Neurosci. 240:1990;1-4.
77. Martyn C. N., Illis L. S., Thom J. Nabilone in the treatment of multiple sclerosis. Lancet. 345:1995;579.
78. Turski L., Klockgether T., Schwarz M., Turski W. A., Sontag K. H. Substantia nigra: A site of action of muscle relaxant drugs. Ann. Neurol. 28:1990;341-348.
79. Gilman S., Newman S. W. Manter and Gatz's Essentials of Clinical Neuroanatomy and Neurophysiology. 1996;Davis, Philadelphia.
80. B. Behav. Pharmacol. 7:1996;299-302.
81. Miller A. S., Walker J. M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur. J. Pharmacol. 279:1995;179-185.
82. Tersigni T. J., Rosenberg H. C. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res. 733:1996;184-192.
83. Sanudo-Pena M. C., Walker J. M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol. 77:1997;1635-1638.
84. 9. J. Neuroimmunol. 23:1989;73-81.
85. Lyman W. D. Drugs of abuse and experimental autoimmune diseases. Friedman H., Specter S., Klein T. W. Drugs of Abuse, Immunity and Immunodeficiency. 1991;81-92 Plenum Press, New York.
86. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology. 28:1994;209-214.
87. Herkenham M., Groen B. G. S., Lynn A. B., De Costa B. R., Richfield E. K. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res. 552:1991;301-310.
88. Skaper S. D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., Leon A. The aliamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA. 93:1996;3984-3989.
89. 452+ND. Brain Res. 622:1993;79-85.
90. Eshhar N., Striem S., Kohen R., Tirosh O., Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 283:1995;19-29.
91. Biegon A., Joseph A. B. Development of HU-211 as a neuroprotectant for ischemic brain damage. Neurol. Res. 17:1995;275-280.
92. Mechoulam R., Lander N., Srebnik M., Breuer A., Segal M., Feigenbaum J. J., Jarbe T. U. C., Consroe P. Stereochemical requirements for cannabimimetic activity. Rapaka R. S., Makriyannis A. Structure-Activity Relationships of the Cannabinoids. 1987;15-30 NIDA Research Monograph 79, Rockville.
93. Zeltser R., Seltzer Z., Eisen A., Feigenbaum J. J., Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain. 47:1991;95-103.
94. Hampson A. J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)-Δ-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA. 95:1998;8268-8273.
95. Dawson V. L., Dawson T. M. Nitric oxide neurotoxicity. J. Chem. Neuroanat. 10:1996;179-190.
96. Menza M. A simple model of the interactions of dopamine, acetylcholine and GABA in movement disorders seen in psychiatry. Med. Hypothesis. 27:1988;285-288.
97. Rao T. S., Cler J. A., Mick S. J., Emmett M. R., Farah J. M., Contreras P. C., Iyengar S., Wood P. L. Neurochemical interactions of competitiveND. J. Neurochem. 56:1991;907-913.
98. Olney J. W. Excitatory amino acids and neuropsychiatric disorders. Annu. Rev. Pharmacol. Toxicol. 30:1990;47-71.
99. Tamminga C. A., Schwarcz R., Macdonald M. E. Huntington's disease: From disease to gene. Am. J. Psychiatr. 154:1997;6.
100. Fischer K. M. Etiology of (CAG)n triplet repeat neurodegenerative diseases such as Huntington's disease is connected to stimulation of glutamate receptors. Med. Hypotheses. 48:1997;393-398.
101. Conti L. H., Johannesen J., Musty R., Consroe P. Anti-dyskinetic effects of cannabidiol. Chesher G., Consroe P., Musty R. Marijuana: An International Research Report. National Campaign Against Drug Abuse Monograph Series. 1988;153-156 Australian Government Publishing Service, Canberra.
102. Sandyk R., Consroe P., Stern L., Snider S. R., Bliklen D. Preliminary trial of cannabidiol in Huntington's disease. Chesher G., Consroe P., Musty R. Marijuana: An International Research Report. National Campaign Against Drug Abuse Monograph Series. 1988;157-162 Australian Government Publishing Service, Canberra.
103. Consroe P., Laguna J., Allender J., Snider S. R., Stern L., Sandyk R., Kennedy K., Schram K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40:1991;701-708.
104. Chesselet M. F., Delfs J. M. Basal ganglia and movement disorders: An update. Trends Neurosci. 19:1996;417-422.
105. Miller A. S., Walker M. J. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur. J. Pharmacol. 304:1996;29-35.
106. Glass M., Faull R. L. M., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience. 56:1993;523-527.
107. Richfield E. K., Herkenham M. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36:1994;577-584.
108. Eidelberg D., Moeller J. R., Antonini A., Kazumata K., Dhawan V., Budman C., Feigin A. The metabolic anatomy of Tourette's syndrome. Neurology. 48:1997;927-934.
109. Sandyk R., Awerbuch G. Marijuana and Tourette's syndrome. J. Clin. Psychopharmacol. 8:1988;444-445.
110. Hemming M., Yellowlees P. M. Effective treatment of Tourette's syndrome with marijuana. J. Psychopharmacol. 7:1993;389-391.
111. French E. D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. NeuroReport. 8:1997;649-652.
112. 1. Neurosci. Lett. 226:1997;159-162.
113. 1. Science. 276:1997;2048-2050.
114. Rodriguez de Fonseca F., Carrera M. R. A., Koob G. F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
115. Naumann M., Becker G., Toyka K. V., Supprian T., Reiners K. Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography. Neurology. 47:1996;1284-1290.
116. Eidelberg D., Moeller J. R., Ishikawa T., Dhawan V., Spetsieris P., Przedborski S., Fahn S. The metabolic topography of idiopathic torsion dystonia. Brain. 118:1995;1473-1484.
117. Reynolds J. R. Therapeutic uses and toxic effects of Cannabis indica. Lancet. 1:1890;637-638.
118. Consroe P., Musty R., Conti L. Effects of cannabidiol in animal models of neurological dysfunction. Chesher G., Consroe P., Musty R. Marijuana: An International Research Report. National Campaign Against Drug Abuse Monograph Series. 1988;147-152 Australian Government Publishing Service, Canberra.
119. Consroe P., Sandyk R., Snider S. R. Effects of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30:1986;277-282.
120. Maneuf Y. P., Crossman A. R., Brotchie J. M. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse. 22:1996;382-385.
121. 9. Eur. J. Pharmacol. 308:1996;161-164.
122. Vingerhoets F. J. G., Schulzer M., Calne D. B., Snow B. J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion. Ann. Neurol. 41:1997;58-64.
123. Frankel J. P., Hughes A., Lees A. J., Stern G. M. Marijuana for Parkinsonian tremor. J. Neurol. Neurosurg. Psychiatr. 53:1990;436.
124. Gifford A. N., Samiian L., Gatley S. J., Ashby C. R. Jr. Examination of the effects of the cannabinoid receptor agonist, CP 55,9940, on electrically evoked transmitter release from rat brain slices. Eur. J. Pharmacol. 324:1997;187-192.
125. 99. Neuropharmacology. 17:1978;137-144.
126. Anderson J. J., Kask A. M., Chase T. N. Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. Eur. J. Pharmacol. 295:1996;163-169.
127. 21. Exp. Neurol. 148:1997;265-270.
128. 9. Pharmacol. Biochem. Behav. 47:1994;33-40.
129. 9. Pharmacol. Biochem. Behav. 51:1995;731-737.
130. 9. Mol. Brain Res. 46:1997;100-108.
131. 9. NeuroReport. 5:1994;761-765.
132. Keeler M. H., Reifler C. B. Grand mal convulsions subsequent to marijuana use. Dis. Nerv. Syst. 28:1967;474-475.
133. Consroe P., Wood G. C., Buchsbaum H. Anticonvulsant nature of marihuana smoking. J. Am. Med. Assoc. 234:1975;306-307.
134. Ellison W. R., Gelwan E., Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J. Clin. Psychiatr. 51:1990;439-440.
135. Ng S. K. C., Brust J. C. M., Hauser W. A., Susser M. Illicit drug use and the risk of new-onset seizures. Am. J. Epidemiol. 132:1990;47-57.
136. Davis J. P., Ramsey H. H. Anti-epileptic action of marijuana-active substances. Fed. Proc. 8:1949;284.
137. Cunha J. M., Carlini E. A., Pereira A. E., Ramos O. L., Pimentel C., Gagliardi R., Sanvito W. L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 21:1980;175-185.
138. Ames F. R. Anticonvulsant effect of cannabidiol. S. Afr. Med. J. 69:1986;14.
139. Trembly, B. Sherman, M. 1990, Double-Blind Clinical Study of Cannabidiol as a Secondary Anticonvulsant.
140. Consroe P., Mechoulam R. Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers. Rapaka R. S., Makriyannis A. Structure-Activity Relationships of the Cannabinoids. 1987;59-66 NIDA Research Monograph 79, Rockville.
141. 9. J. Clin. Pharmacol. 15:1975;139-143.
142. 9. J. Clin. Pharmacol. 18:1975;84-89.
143. Lindblom, U. Lindstrom, P. Boreus, L. 1987, Lack of Effect of Cannabidiol in Sustained Neuropathic Pain.
144. Edsall S. A., Knapp R. J., Vanderah T. W., Roeske W. R., Consroe P., Yamamura H. I. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. NeuroReport. 7:1996;593-596.
145. Lichtman A. H., Martin B. R. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol. Biochem. Behav. 57:1997;7-12.
146. Martin W. J., Patrick S. L., Coffin P. O., Tsou K., Walker J. M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 56:1995;2103-2110.
147. Lichtman A. H., Cook S. A., Martin B. R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
148. Martin W. J., Hohmann A. G., Walker J. M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
149. 9. J. Pharmacol. Exp. Ther. 268:1994;1381-1386.
150. Pugh G. Jr., Mason D. J., Combs V., Welch S. P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J. Pharmacol. Exp. Ther. 281:1997;730-737.
151. Herzberg U., Eliav E., Bennett G. J., Kopin I. J. The analgesic effects ofR. Neurosci. Lett. 221:1997;157-160.
152. Richardson J. D., Aanonsen L., Hargreaves K. M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18:1998;451-457.
153. Richardson J. D., Aanonsen L., Hargreaves K. M. Antihyperalgesic effects of spinal cannabinoids. Eur. J. Pharmacol. 345:1998;145-153.
154. 1. Pain. 75:1998;111-119.
155. Calignano A., LaRana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
156. Hampson A. J., Bornheim L. M., Scanziani M., Yost C. S., Gray A. T., Hansen B. M., Leonoudakis D. J., Bickler P. E. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70:1998;671-676.
157. Westlake T. M., Howlett A. C., Bonner T. I., Matsuda L. A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: Anin vitro. Neuroscience. 63:1994;637-652.
158. 9. Psychopharmacology. 126:1996;125-131.
159. Mallet P. E., Beninger R. J. The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav. Pharmacol. 7:1996;276-284.